Drug Detail:Fotivda (Tivozanib)
Generic Name: tivozanib hydrochloride 0.89mg
Dosage Form: capsule
Drug Class: VEGF/VEGFR inhibitors
Drug Detail:Fotivda (Tivozanib)
Generic Name: tivozanib hydrochloride 0.89mg
Dosage Form: capsule
Drug Class: VEGF/VEGFR inhibitors
The recommended dosage of FOTIVDA is 1.34 mg taken orally once daily for 21 days on treatment followed by 7 days off treatment for a 28-day cycle.
Continue treatment until disease progression or until unacceptable toxicity occurs.
Take FOTIVDA with or without food. Swallow the FOTIVDA capsule whole with a glass of water. Do not open the capsule.
If a dose is missed, the next dose should be taken at the next scheduled time. Do not take two doses at the same time.
Initiate medical management for diarrhea, nausea, or vomiting prior to dose interruption or reduction.
If dose modifications are required for adverse reactions, reduce the dosage of FOTIVDA to 0.89 mg for 21 days on treatment followed by 7 days off treatment for a 28-day cycle.
Recommendations for dosage modifications are provided in Table 1.
Adverse Reaction | Severity* | Dosage Modifications for FOTIVDA |
---|---|---|
|
||
Hypertension [see Warnings and Precautions (5.1)] |
Grade 3 |
|
Grade 4 |
|
|
Cardiac Failure [see Warnings and Precautions (5.2)] |
Grade 3 |
|
Grade 4 |
|
|
Arterial Thromboembolic Events [see Warnings and Precautions (5.3)] |
Any Grade |
|
Hemorrhagic Events [see Warnings and Precautions (5.5)] |
Grade 3 or 4 |
|
Proteinuria [see Warnings and Precautions (5.6)] |
2 grams or greater proteinuria in 24 hours |
|
Reverse Posterior Leukoencephalopathy Syndrome [see Warnings and Precautions (5.9)] |
Any Grade |
|
Other Adverse Reactions | Persistent or intolerable Grade 2 or 3 adverse reaction Grade 4 laboratory abnormality |
|
Grade 4 adverse reaction |
|
Reduce the recommended dosage of FOTIVDA to 0.89 mg capsule taken orally once daily for 21 days on treatment followed by 7 days off treatment for a 28-day cycle for patients with moderate hepatic impairment [see Use in Specific Populations (8.7)].